# Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

Study · id `cardio:ct-nct05303857` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05303857](<https://clinicaltrials.gov/study/NCT05303857>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05303857

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

## Technical summary

Registry record NCT05303857. Randomized; triple masking; primary purpose treatment. Start 2022-03-03 (actual); primary completion 2023-12-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 107 participants (enrolled count; ClinicalTrials.gov record NCT05303857, source copy `cardio:ctgov-nct05303857-2025-06-11`, retrieved 2026-10-26)
- Started: 2022-03-03 (actual) (ClinicalTrials.gov record NCT05303857, source copy `cardio:ctgov-nct05303857-2025-06-11`, retrieved 2026-10-26)
- Primary completion: 2023-12-15 (actual) (ClinicalTrials.gov record NCT05303857, source copy `cardio:ctgov-nct05303857-2025-06-11`, retrieved 2026-10-26)
- Completion: 2025-04-17 (actual) (ClinicalTrials.gov record NCT05303857, source copy `cardio:ctgov-nct05303857-2025-06-11`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT05303857, source copy `cardio:ctgov-nct05303857-2025-06-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05303857-2025-06-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
- Acronym: SEMA
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide Pen Injector
- Intervention (Drug): Placebo
- Lead sponsor: University of Erlangen-Nürnberg Medical School
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Erlangen-Nürnberg Medical School (`cardio:org-university-of-erlangen-nurnberg-medical-school`)

## Provenance

Content hash: d511ca0b89b0c39460a08e71b116edf2acaf26a266ea0894df671f6606a00ba8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
